{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:07:24Z","timestamp":1793614044471,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41371-019-0163-5","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T15:05:38Z","timestamp":1547823938000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin"],"prefix":"10.1038","volume":"33","author":[{"given":"Carina","family":"Ureche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tapoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Volovat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Voroneanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"163_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"163_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0378-1119(93)90495-O","volume":"136","author":"BF O\u2019Dowd","year":"1993","unstructured":"O\u2019Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355\u201360.","journal-title":"Gene"},{"key":"163_CR3","doi-asserted-by":"publisher","first-page":"21061","DOI":"10.1074\/jbc.M908417199","volume":"275","author":"M Hosoya","year":"2000","unstructured":"Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275:21061\u20137.","journal-title":"J Biol Chem"},{"key":"163_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2003.08.026","volume":"317","author":"N Zhou","year":"2003","unstructured":"Zhou N, Zhang X, Fan X, Argyris E, Fang J, Acheampong E, et al. The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology. 2003;317:84\u201394.","journal-title":"Virology"},{"key":"163_CR5","first-page":"53","volume":"63","author":"M Kapica","year":"2012","unstructured":"Kapica M, Jankowska A, Antushevich H, Pietrzak P, Bierla JB, Dembinski A, et al. The effect of exogenous apelin on the secretion of pancreatic juice in anaesthetized rats. J Physiol Pharmacol: Off J Pol Physiol Soc. 2012;63:53\u201360.","journal-title":"J Physiol Pharmacol: Off J Pol Physiol Soc"},{"key":"163_CR6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1210\/en.2004-1427","volume":"146","author":"J Boucher","year":"2005","unstructured":"Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764\u201371.","journal-title":"Endocrinology"},{"key":"163_CR7","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1073\/pnas.0403518101","volume":"101","author":"N Mota De","year":"2004","unstructured":"De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA. 2004;101:10464\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"163_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/ASN.2007070816","volume":"19","author":"M Azizi","year":"2008","unstructured":"Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol: Jasn. 2008;19:1015\u201324.","journal-title":"J Am Soc Nephrol: Jasn"},{"key":"163_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.109.134619","volume":"54","author":"JJ Maguire","year":"2009","unstructured":"Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertens (Dallas, Tex: 1979). 2009;54:598\u2013604.","journal-title":"Hypertens (Dallas, Tex: 1979)"},{"key":"163_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pharmthera.2005.04.001","volume":"107","author":"MJ Kleinz","year":"2005","unstructured":"Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107:198\u2013211.","journal-title":"Pharmacol Ther"},{"key":"163_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.regpep.2003.11.002","volume":"118","author":"MJ Kleinz","year":"2004","unstructured":"Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118:119\u201325.","journal-title":"Regul Pept"},{"key":"163_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","volume":"65","author":"AL Brame","year":"2015","unstructured":"Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertens (Dallas, Tex: 1979). 2015;65:834\u201340.","journal-title":"Hypertens (Dallas, Tex: 1979)"},{"key":"163_CR13","first-page":"547","volume":"22","author":"J Hamada","year":"2008","unstructured":"Hamada J, Kimura J, Ishida J, Kohda T, Morishita S, Ichihara S, et al. Evaluation of novel cyclic analogues of apelin. Int J Mol Med. 2008;22:547\u201352.","journal-title":"Int J Mol Med"},{"key":"163_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.peptides.2012.09.003","volume":"38","author":"ZQ Jia","year":"2012","unstructured":"Jia ZQ, Hou L, Leger A, Wu I, Kudej AB, Stefano J, et al. Cardiovascular effects of a PEGylated apelin. Peptides. 2012;38:181\u20138.","journal-title":"Peptides"},{"key":"163_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1096\/fj.201600784R","volume":"31","author":"R Gerbier","year":"2017","unstructured":"Gerbier R, Alvear-Perez R, Margathe JF, Flahault A, Couvineau P, Gao J, et al. Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects. FASEB J: Off Publ Fed Am Soc Exp Biol. 2017;31:687\u2013700.","journal-title":"FASEB J: Off Publ Fed Am Soc Exp Biol"},{"key":"163_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1471-4159.2000.0740034.x","volume":"74","author":"DK Lee","year":"2000","unstructured":"Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34\u201341.","journal-title":"J Neurochem"},{"key":"163_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1476-5381.2012.02192.x","volume":"168","author":"K Siddiquee","year":"2013","unstructured":"Siddiquee K, Hampton J, McAnally D, May L, Smith L. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol. 2013;168:1104\u201317.","journal-title":"Br J Pharmacol"},{"key":"163_CR18","doi-asserted-by":"publisher","first-page":"H2540","DOI":"10.1152\/ajpheart.00046.2008","volume":"294","author":"C Wang","year":"2008","unstructured":"Wang C, Du JF, Wu F, Wang HC. Apelin decreases the SR Ca2+content but enhances the amplitude of [Ca2+]i transient and contractions during twitches in isolated rat cardiac myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H2540\u20136.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"163_CR19","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1172\/JCI69608","volume":"123","author":"T Sato","year":"2013","unstructured":"Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest. 2013;123:5203\u201311.","journal-title":"J Clin Invest"},{"key":"163_CR20","first-page":"3","volume":"88","author":"CM Goidescu","year":"2015","unstructured":"Goidescu CM, Vida-Simiti LA. The apelin-APJ system in the evolution of heart failure. Clujul Med (1957). 2015;88:3\u20138.","journal-title":"Clujul Med (1957)"},{"key":"163_CR21","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1007\/s11033-014-3552-4","volume":"41","author":"D Wu","year":"2014","unstructured":"Wu D, He L, Chen L. Apelin\/APJ system: a promising therapy target for hypertension. Mol Biol Rep. 2014;41:6691\u2013703.","journal-title":"Mol Biol Rep"},{"key":"163_CR22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacc.2008.06.013","volume":"52","author":"AG Japp","year":"2008","unstructured":"Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52:908\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"163_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.115.06892","volume":"68","author":"W Wang","year":"2016","unstructured":"Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: Physiological effects in the cardiovascular system. Hypertens (Dallas, Tex: 1979). 2016;68:365\u201377.","journal-title":"Hypertens (Dallas, Tex: 1979)"},{"key":"163_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tice.2017.10.009","volume":"51","author":"VN Izgut-Uysal","year":"2018","unstructured":"Izgut-Uysal VN, Acar N, Birsen I, Ozcan F, Ozbey O, Soylu H, et al. Apelin-APJ system is responsible for stress-induced increase in atrial natriuretic peptide expression in rat heart. Tissue Cell. 2018;51:91\u20136.","journal-title":"Tissue Cell"},{"key":"163_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1161\/01.ATV.0000218841.39828.91","volume":"26","author":"T Hashimoto","year":"2006","unstructured":"Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006;26:1267\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"163_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cardiores.2004.08.018","volume":"65","author":"EA Ashley","year":"2005","unstructured":"Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65:73\u201382.","journal-title":"Cardiovasc Res"},{"issue":"11Suppl 1","key":"163_CR27","first-page":"Ii187","volume":"110","author":"MF Berry","year":"2004","unstructured":"Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin Has vivo inotropic Eff Norm Fail Hearts Circ. 2004;110(11Suppl 1):Ii187\u201393.","journal-title":"Apelin Has vivo inotropic Eff Norm Fail Hearts Circ"},{"key":"163_CR28","doi-asserted-by":"publisher","first-page":"H2308","DOI":"10.1152\/ajpheart.01177.2010","volume":"300","author":"R Rastaldo","year":"2011","unstructured":"Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G, et al. Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol. 2011;300:H2308\u201315.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"163_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1089\/ars.2010.3355","volume":"14","author":"R Rastaldo","year":"2011","unstructured":"Rastaldo R, Cappello S, Folino A, Losano G. Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antioxid Redox Signal. 2011;14:909\u201322.","journal-title":"Antioxid Redox Signal"},{"key":"163_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000033522.37861.69","volume":"91","author":"I Szokodi","year":"2002","unstructured":"Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434\u201340.","journal-title":"Circ Res"},{"key":"163_CR31","doi-asserted-by":"publisher","first-page":"e93473","DOI":"10.1371\/journal.pone.0093473","volume":"9","author":"A Perjes","year":"2014","unstructured":"Perjes A, Skoumal R, Tenhunen O, Konyi A, Simon M, Horvath IG, et al. Apelin increases cardiac contractility via protein kinase Cepsilon- and extracellular signal-regulated kinase-dependent mechanisms. PLoS ONE. 2014;9:e93473.","journal-title":"PLoS ONE"},{"key":"163_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejphar.2006.09.034","volume":"553","author":"T Dai","year":"2006","unstructured":"Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553:222\u20138.","journal-title":"Eur J Pharmacol"},{"key":"163_CR33","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbrc.2007.04.017","volume":"357","author":"K Farkasfalvi","year":"2007","unstructured":"Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007;357:889\u201395.","journal-title":"Biochem Biophys Res Commun"},{"key":"163_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1515\/folmed-2017-0066","volume":"60","author":"S Koval","year":"2018","unstructured":"Koval S, Iushko K, Starchenko T. Relations of apelin with cardiac remodeling in patients with hypertension and type 2 diabetes. Folia Med (Plovdiv). 2018;60:117\u201323.","journal-title":"Folia Med (Plovdiv)"},{"key":"163_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0635-5","volume":"13","author":"L Ye","year":"2015","unstructured":"Ye L, Ding F, Zhang L, Shen A, Yao H, Deng L, et al. Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients. J Transl Med. 2015;13:290.","journal-title":"J Transl Med"},{"key":"163_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.bbadis.2015.02.013","volume":"1852","author":"H Chen","year":"2015","unstructured":"Chen H, Wan D, Wang L, Peng A, Xiao H, Petersen RB, et al. Apelin protects against acute renal injury by inhibiting TGF-beta1. Biochim Biophys Acta. 2015;1852:1278\u201387.","journal-title":"Biochim Biophys Acta"},{"key":"163_CR37","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.febslet.2010.04.025","volume":"584","author":"C Foussal","year":"2010","unstructured":"Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, et al. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 2010;584:2363\u201370.","journal-title":"FEBS Lett"},{"key":"163_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/apha.12342","volume":"212","author":"F Zhang","year":"2014","unstructured":"Zhang F, Sun HJ, Xiong XQ, Chen Q, Li YH, Kang YM, et al. Apelin-13 and APJ in paraventricular nucleus contribute to hypertension via sympathetic activation and vasopressin release in spontaneously hypertensive rats. Acta Physiol (Oxf). 2014;212:17\u201327.","journal-title":"Acta Physiol (Oxf)"},{"key":"163_CR39","doi-asserted-by":"publisher","first-page":"H605","DOI":"10.1152\/ajpheart.00366.2012","volume":"303","author":"L Li","year":"2012","unstructured":"Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012;303:H605\u201318.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"163_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2016.11.215","volume":"230","author":"L Lu","year":"2017","unstructured":"Lu L, Wu D, Li L, Chen L. Apelin\/APJ system: A bifunctional target for cardiac hypertrophy. Int J Cardiol. 2017;230:164\u201370.","journal-title":"Int J Cardiol"},{"key":"163_CR41","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.bcp.2007.12.015","volume":"75","author":"AG Japp","year":"2008","unstructured":"Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol. 2008;75:1882\u201392.","journal-title":"Biochem Pharmacol"},{"key":"163_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejheart.2005.10.007","volume":"8","author":"KS Chong","year":"2006","unstructured":"Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355\u201360.","journal-title":"Eur J Heart Fail"},{"key":"163_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejheart.2006.06.005","volume":"9","author":"P Francia","year":"2007","unstructured":"Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail. 2007;9:306\u20139.","journal-title":"Eur J Heart Fail"},{"key":"163_CR44","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cbic.201600244","volume":"17","author":"SM McKinnie","year":"2016","unstructured":"McKinnie SM, Fischer C, Tran KM, Wang W, Mosquera F, Oudit GY, et al. The metalloprotease neprilysin degrades and inactivates apelin peptides. Chembiochem: a Eur J Chem Biol. 2016;17:1495\u20138.","journal-title":"Chembiochem: a Eur J Chem Biol"},{"key":"163_CR45","first-page":"690","volume":"32","author":"M Topuz","year":"2016","unstructured":"Topuz M, Cosgun M, Akkus O, Bulut A, Sen O, Topuz AN, et al. Effect of spironolactone on plasma apelin-12 levels in patients with chronic systolic heart failure. Acta Cardiol Sin. 2016;32:690\u20137.","journal-title":"Acta Cardiol Sin"},{"key":"163_CR46","first-page":"137","volume":"76","author":"W Koguchi","year":"2012","unstructured":"Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circulation journal: official journal of the Japanese Circulation. Society. 2012;76:137\u201344.","journal-title":"Society"},{"key":"163_CR47","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.peptides.2009.02.010","volume":"30","author":"XJ Zeng","year":"2009","unstructured":"Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS. Apelin protects heart against ischemia\/reperfusion injury in rat. Peptides. 2009;30:1144\u201352.","journal-title":"Peptides"},{"key":"163_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/CIRCHEARTFAILURE.111.000077","volume":"6","author":"GD Barnes","year":"2013","unstructured":"Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6:482\u201391.","journal-title":"Circ Heart Fail"},{"key":"163_CR49","first-page":"3343","volume":"118","author":"HJ Chun","year":"2008","unstructured":"Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343\u201354.","journal-title":"J Clin Invest"},{"key":"163_CR50","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/j.1365-2362.2012.02728.x","volume":"42","author":"NP Kadoglou","year":"2012","unstructured":"Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Kostakis A, et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability. Eur J Clin Invest. 2012;42:1278\u201386.","journal-title":"Eur J Clin Invest"},{"key":"163_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5507\/bp.2017.002","volume":"161","author":"A Smekal","year":"2017","unstructured":"Smekal A, Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161:31\u201340.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"163_CR52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1536\/ihj.13-234","volume":"55","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J. 2014;55:204\u201312.","journal-title":"Int Heart J"},{"key":"163_CR53","first-page":"59","volume":"7","author":"A Mortazavi","year":"2018","unstructured":"Mortazavi A, Nematipoor E, Djalali M, Keshavarz SA, Samavat S, Zarei M, et al. The effect of omega-3 fatty acids on serum apelin levels in cardiovascular disease: A randomized, double-blind, placebo-controlled trial. Rep Biochem & Mol Biol. 2018;7:59\u201366.","journal-title":"Rep Biochem & Mol Biol"},{"issue":"3","key":"163_CR54","doi-asserted-by":"publisher","first-page":"e12891","DOI":"10.1111\/eci.12891","volume":"48","author":"Rodrigo A. Fraga-Silva","year":"2018","unstructured":"Fraga-Silva RA, Seeman H, Montecucco F, da Silva AR, Burger F, Costa-Fraga FP, et al. Apelin-13 treatment enhances the stability of atherosclerotic plaques. Eur J Clin Invest; 2018;48:e12891.","journal-title":"European Journal of Clinical Investigation"},{"key":"163_CR55","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1096\/fj.06-7294com","volume":"21","author":"VP Ronkainen","year":"2007","unstructured":"Ronkainen VP, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J: Off Publ Fed Am Soc Exp Biol. 2007;21:1821\u201330.","journal-title":"FASEB J: Off Publ Fed Am Soc Exp Biol"},{"key":"163_CR56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pharmthera.2007.06.005","volume":"116","author":"DJ Hausenloy","year":"2007","unstructured":"Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther. 2007;116:173\u201391.","journal-title":"Pharmacol Ther"},{"key":"163_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/eci.12012","volume":"43","author":"CC Cheng","year":"2013","unstructured":"Cheng CC, Weerateerangkul P, Lu YY, Chen YC, Lin YK, Chen SA, et al. Apelin regulates the electrophysiological characteristics of atrial myocytes. Eur J Clin Invest. 2013;43:34\u201340.","journal-title":"Eur J Clin Invest"},{"key":"163_CR58","doi-asserted-by":"publisher","first-page":"e12580","DOI":"10.1097\/MD.0000000000012580","volume":"97","author":"YZ Wang","year":"2018","unstructured":"Wang YZ, Fan J, Zhong B, Xu Q. Apelin: A novel prognostic predictor for atrial fibrillation recurrence after pulmonary vein isolation. Medicine. 2018;97:e12580.","journal-title":"Medicine"},{"key":"163_CR59","first-page":"5285392","volume":"2018","author":"A Salska","year":"2018","unstructured":"Salska A, Dziuba M, Salski W, Chizynski K, Zielinska M. Apelin Atr Fibrillation: Role Arrhythmia Recurrence Progn. 2018;2018:5285392.","journal-title":"Apelin Atr Fibrillation: Role Arrhythmia Recurrence Progn"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0163-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:38Z","timestamp":1684617818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1038\/s41371-019-0163-5","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}